QQQ   417.36 (-1.43%)
AAPL   165.18 (-1.11%)
MSFT   399.41 (-1.20%)
META   483.15 (-3.72%)
GOOGL   153.96 (-1.31%)
AMZN   174.80 (-2.47%)
TSLA   148.83 (-0.73%)
NVDA   812.71 (-4.02%)
AMD   148.84 (-4.02%)
NIO   3.84 (-4.00%)
BABA   68.66 (-0.32%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.35 (-2.35%)
CGC   8.10 (+3.45%)
DIS   112.00 (-0.38%)
AMC   3.24 (+10.96%)
PFE   25.79 (+1.58%)
PYPL   62.22 (+0.19%)
XOM   120.22 (+1.43%)
QQQ   417.36 (-1.43%)
AAPL   165.18 (-1.11%)
MSFT   399.41 (-1.20%)
META   483.15 (-3.72%)
GOOGL   153.96 (-1.31%)
AMZN   174.80 (-2.47%)
TSLA   148.83 (-0.73%)
NVDA   812.71 (-4.02%)
AMD   148.84 (-4.02%)
NIO   3.84 (-4.00%)
BABA   68.66 (-0.32%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.35 (-2.35%)
CGC   8.10 (+3.45%)
DIS   112.00 (-0.38%)
AMC   3.24 (+10.96%)
PFE   25.79 (+1.58%)
PYPL   62.22 (+0.19%)
XOM   120.22 (+1.43%)
QQQ   417.36 (-1.43%)
AAPL   165.18 (-1.11%)
MSFT   399.41 (-1.20%)
META   483.15 (-3.72%)
GOOGL   153.96 (-1.31%)
AMZN   174.80 (-2.47%)
TSLA   148.83 (-0.73%)
NVDA   812.71 (-4.02%)
AMD   148.84 (-4.02%)
NIO   3.84 (-4.00%)
BABA   68.66 (-0.32%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.35 (-2.35%)
CGC   8.10 (+3.45%)
DIS   112.00 (-0.38%)
AMC   3.24 (+10.96%)
PFE   25.79 (+1.58%)
PYPL   62.22 (+0.19%)
XOM   120.22 (+1.43%)
QQQ   417.36 (-1.43%)
AAPL   165.18 (-1.11%)
MSFT   399.41 (-1.20%)
META   483.15 (-3.72%)
GOOGL   153.96 (-1.31%)
AMZN   174.80 (-2.47%)
TSLA   148.83 (-0.73%)
NVDA   812.71 (-4.02%)
AMD   148.84 (-4.02%)
NIO   3.84 (-4.00%)
BABA   68.66 (-0.32%)
T   16.37 (+0.24%)
F   12.12 (+0.50%)
MU   107.74 (-3.74%)
GE   149.35 (-2.35%)
CGC   8.10 (+3.45%)
DIS   112.00 (-0.38%)
AMC   3.24 (+10.96%)
PFE   25.79 (+1.58%)
PYPL   62.22 (+0.19%)
XOM   120.22 (+1.43%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$106.94
+1.6%
$114.28
$89.67
$121.64
$185.56B0.745.67 million shs3.54 million shs
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$125.59
+0.3%
$126.17
$99.14
$133.10
$318.12B0.388.24 million shs2.84 million shs
Novartis AG stock logo
NVS
Novartis
$93.99
+1.5%
$98.22
$92.19
$108.78
$199.22B0.541.48 million shs1.24 million shs
Pfizer Inc. stock logo
PFE
Pfizer
$25.79
+1.6%
$27.14
$25.23
$40.37
$146.04B0.6142.15 million shs17.90 million shs
Roche Holding AG stock logo
RHHBY
Roche
$30.05
-0.1%
$32.11
$29.95
$40.48
N/A0.393.17 million shs2.08 million shs
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Abbott Laboratories stock logo
ABT
Abbott Laboratories
-0.59%-5.52%-6.94%-8.26%-6.25%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-0.14%-0.75%+2.44%+5.30%+9.68%
Novartis AG stock logo
NVS
Novartis
-0.56%-1.88%-3.88%-14.47%-5.56%
Pfizer Inc. stock logo
PFE
Pfizer
-0.08%-3.61%-8.06%-10.27%-36.92%
Roche Holding AG stock logo
RHHBY
Roche
-0.10%-2.94%-6.44%-14.97%-21.81%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Abbott Laboratories stock logo
ABT
Abbott Laboratories
4.9951 of 5 stars
3.45.04.24.53.72.52.5
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
4.7448 of 5 stars
2.35.03.34.13.92.51.3
Novartis AG stock logo
NVS
Novartis
2.4101 of 5 stars
2.13.02.50.02.40.02.5
Pfizer Inc. stock logo
PFE
Pfizer
4.9926 of 5 stars
3.25.04.24.83.11.73.1
Roche Holding AG stock logo
RHHBY
Roche
2.4934 of 5 stars
3.02.01.70.02.40.01.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Abbott Laboratories stock logo
ABT
Abbott Laboratories
2.75
Moderate Buy$121.3113.44% Upside
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
2.58
Moderate Buy$131.254.51% Upside
Novartis AG stock logo
NVS
Novartis
2.25
Hold$114.0021.29% Upside
Pfizer Inc. stock logo
PFE
Pfizer
2.35
Hold$36.8842.98% Upside
Roche Holding AG stock logo
RHHBY
Roche
2.00
Hold$40.0033.11% Upside

Current Analyst Ratings

Latest NVS, MRK, PFE, ABT, and RHHBY Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/18/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$128.00 ➝ $125.00
4/18/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/15/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
4/8/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Berenberg Bank
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$140.00 ➝ $143.00
4/5/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
4/4/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$120.00 ➝ $125.00
4/3/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$126.00 ➝ $128.00
4/1/2024
Pfizer Inc. stock logo
PFE
Pfizer
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$45.00
3/28/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$139.00 ➝ $142.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Overweight$135.00
3/27/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetEqual Weight ➝ Equal Weight$130.00 ➝ $135.00
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$40.11B4.63$6.42 per share16.65$22.36 per share4.78
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$60.12B5.29$3.05 per share41.21$14.85 per share8.46
Novartis AG stock logo
NVS
Novartis
$45.44B4.38$10.82 per share8.69$22.06 per share4.26
Pfizer Inc. stock logo
PFE
Pfizer
$58.50B2.50$3.02 per share8.54$15.81 per share1.63
Roche Holding AG stock logo
RHHBY
Roche
$65.37BN/A$3.10 per share9.68$4.91 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$5.72B$3.2133.3120.812.5513.96%20.32%10.59%7/18/2024 (Estimated)
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$365M$0.14897.0712.781.630.61%9.33%3.61%4/25/2024 (Confirmed)
Novartis AG stock logo
NVS
Novartis
$14.85B$7.1813.0911.791.4529.83%29.90%12.97%4/23/2024 (Estimated)
Pfizer Inc. stock logo
PFE
Pfizer
$2.12B$0.3671.649.311.153.62%10.88%4.91%5/1/2024 (Confirmed)
Roche Holding AG stock logo
RHHBY
Roche
$12.81BN/A0.0011.254.38N/AN/AN/AN/A

Latest NVS, MRK, PFE, ABT, and RHHBY Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/1/2024N/A
Pfizer Inc. stock logo
PFE
Pfizer
$0.57N/A-$0.57N/AN/AN/A  
4/25/2024N/A
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$2.12N/A-$2.12N/AN/AN/A  
4/17/2024Q1 24
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$0.96$0.98+$0.02$1.26$9.88 billion$9.96 billion    
2/1/2024Q4 2023
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
-$0.09$0.03+$0.12$0.54$14.49 billion$14.63 billion    
1/30/202412/31/2023
Novartis AG stock logo
NVS
Novartis
$1.64$1.53-$0.11-$1.08$11.69 billion$11.42 billion    
1/30/202412/31/2023
Pfizer Inc. stock logo
PFE
Pfizer
-$0.19$0.10+$0.29$0.80$14.37 billion$14.25 billion    
1/24/202412/31/2023
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$1.19$1.19N/A$1.47$10.19 billion$10.24 billion    

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Abbott Laboratories stock logo
ABT
Abbott Laboratories
$2.202.06%+12.31%68.54%53 Years
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
$3.082.45%+6.08%2,200.00%13 Years
Novartis AG stock logo
NVS
Novartis
$2.432.59%+4.26%33.84%4 Years
Pfizer Inc. stock logo
PFE
Pfizer
$1.686.51%+2.57%466.67%15 Years
Roche Holding AG stock logo
RHHBY
Roche
$0.882.93%N/AN/AN/A

Latest NVS, MRK, PFE, ABT, and RHHBY Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
2/16/2024
Abbott Laboratories stock logo
ABT
Abbott Laboratories
quarterly$0.551.9%4/12/20244/15/20245/15/2024
1/23/2024
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
quarterly$0.772.6%3/14/20243/15/20244/5/2024
3/1/2024
Novartis AG stock logo
NVS
Novartis
annual$3.77723.1%3/7/20243/8/20243/7/2024
(Data available from 1/1/2013 forward)

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Abbott Laboratories stock logo
ABT
Abbott Laboratories
0.35
1.64
1.16
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.89
1.25
1.00
Novartis AG stock logo
NVS
Novartis
0.39
1.15
0.93
Pfizer Inc. stock logo
PFE
Pfizer
0.69
0.91
0.69
Roche Holding AG stock logo
RHHBY
Roche
0.75
1.35
1.04

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
75.18%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
76.07%
Novartis AG stock logo
NVS
Novartis
13.12%
Pfizer Inc. stock logo
PFE
Pfizer
68.36%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Insider Ownership

CompanyInsider Ownership
Abbott Laboratories stock logo
ABT
Abbott Laboratories
1.10%
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
0.20%
Novartis AG stock logo
NVS
Novartis
0.01%
Pfizer Inc. stock logo
PFE
Pfizer
0.06%
Roche Holding AG stock logo
RHHBY
Roche
N/A

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Abbott Laboratories stock logo
ABT
Abbott Laboratories
114,0001.74 billion1.72 billionOptionable
Merck & Co., Inc. stock logo
MRK
Merck & Co., Inc.
72,0002.53 billion2.53 billionOptionable
Novartis AG stock logo
NVS
Novartis
76,0572.12 billion2.12 billionOptionable
Pfizer Inc. stock logo
PFE
Pfizer
88,0005.66 billion5.66 billionOptionable
Roche Holding AG stock logo
RHHBY
Roche
103,605N/AN/ANot Optionable

NVS, MRK, PFE, ABT, and RHHBY Headlines

SourceHeadline
Roche (RHHBY) Alecensa Wins FDA Nod for Label ExpansionRoche (RHHBY) Alecensa Wins FDA Nod for Label Expansion
zacks.com - April 19 at 11:16 AM
F. Hoffmann-La Roche Ltd: FDA approves Roches Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerF. Hoffmann-La Roche Ltd: FDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finanznachrichten.de - April 19 at 3:29 AM
FDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerFDA approves Roche’s Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
finance.yahoo.com - April 19 at 3:29 AM
Roche Announces FDA Approval For AlecensaRoche Announces FDA Approval For Alecensa
markets.businessinsider.com - April 19 at 3:29 AM
FDA approves Roches Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancerFDA approves Roche's Alecensa as the first adjuvant treatment for people with ALK-positive early-stage lung cancer
globenewswire.com - April 19 at 1:00 AM
FDA Approves Genentechs Alecensa For ALK-positive Early-Stage Lung CancerFDA Approves Genentech's Alecensa For ALK-positive Early-Stage Lung Cancer
markets.businessinsider.com - April 18 at 10:08 PM
FDA Approves Genentechs Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung CancerFDA Approves Genentech's Alecensa as First Adjuvant Treatment for People With ALK-Positive Early-Stage Lung Cancer
businesswire.com - April 18 at 4:35 PM
Genentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MSGenentech’s Subcutaneous Ocrevus One-Year Data Demonstrates Near-Complete Suppression of Clinical Relapses and Brain Lesions in Patients With Progressive and Relapsing Forms of MS
finance.yahoo.com - April 17 at 10:38 AM
Celebration Obstetrics & Gynecology Now Accepting Partners Direct Health InsuranceCelebration Obstetrics & Gynecology Now Accepting Partner's Direct Health Insurance
finance.yahoo.com - April 16 at 1:44 PM
Roches Lymphoma Drug With Chemo Extends Survival In Pretreated PatientsRoche's Lymphoma Drug With Chemo Extends Survival In Pretreated Patients
msn.com - April 15 at 3:19 PM
Roches (RHHBY) Combination Therapy Meets Goal in Lymphoma StudyRoche's (RHHBY) Combination Therapy Meets Goal in Lymphoma Study
zacks.com - April 15 at 8:36 AM
Genentechs Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO StudyGenentech's Columvi Meets Primary Endpoint of Overall Survival in People With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in Phase III STARGLO Study
businesswire.com - April 15 at 1:10 AM
[Ad hoc announcement pursuant to Art. 53 LR] Roches Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study[Ad hoc announcement pursuant to Art. 53 LR] Roche's Columvi meets primary endpoint of overall survival in people with relapsed or refractory diffuse large B-cell lymphoma in Phase III STARGLO study
globenewswire.com - April 15 at 1:00 AM
Guru Fundamental Report for RHHBYGuru Fundamental Report for RHHBY
nasdaq.com - April 13 at 12:02 AM
Why Roche Holdings Stock Popped TodayWhy Roche Holdings Stock Popped Today
fool.com - April 11 at 6:33 PM
F. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimers disease diagnosisF. Hoffmann-La Roche Ltd: Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
finanznachrichten.de - April 11 at 9:52 AM
Roches Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimers DetectionRoche's Elecsys PTau217 Blood Test Receives FDA Breakthrough Designation For Alzheimer's Detection
markets.businessinsider.com - April 11 at 9:52 AM
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimers disease diagnosisRoche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
globenewswire.com - April 11 at 1:00 AM
Roche Gets CE Mark For First Companion Diagnostic To Identify HER2-low Metastatic Breast CancerRoche Gets CE Mark For First Companion Diagnostic To Identify HER2-low Metastatic Breast Cancer
markets.businessinsider.com - April 10 at 9:06 AM
Roche companion diagnostic test wins CE Mark to identify metastatic breast cancer patientsRoche companion diagnostic test wins CE Mark to identify metastatic breast cancer patients
msn.com - April 10 at 9:06 AM
Roche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTURoche obtains CE Mark for first companion diagnostic to identify patients with HER2-low metastatic breast cancer eligible for ENHERTU
prnewswire.com - April 10 at 1:00 AM
Meet Europes Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.Meet Europe's Mag 18. Novo Nordisk Stock, ASML, and Others Can Rival the Mag Seven.
barrons.com - April 9 at 11:42 AM
Veracode Embarks on a New Chapter with Appointment of Brian Roche as Chief Executive OfficerVeracode Embarks on a New Chapter with Appointment of Brian Roche as Chief Executive Officer
businesswire.com - April 3 at 12:36 PM
F. Hoffmann-La Roche Ltd: Roche receives FDA approval for the first molecular test to screen for malaria in blood donorsF. Hoffmann-La Roche Ltd: Roche receives FDA approval for the first molecular test to screen for malaria in blood donors
finanznachrichten.de - March 27 at 10:19 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Abbott Laboratories logo

Abbott Laboratories

NYSE:ABT
Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.
Merck & Co., Inc. logo

Merck & Co., Inc.

NYSE:MRK
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. The company serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians, wholesalers, government entities, veterinarians, distributors, animal producers, farmers, and pet owners. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.
Novartis logo

Novartis

NYSE:NVS
Novartis AG researches, develops, manufactures, and markets healthcare products in Switzerland and internationally. It offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran, a therapy to reduce LDL cholesterol. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
Pfizer logo

Pfizer

NYSE:PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Roche logo

Roche

OTCMKTS:RHHBY
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation. It is also developing products for various therapeutic areas. In addition, it offers in vitro tests for the diagnosis of various diseases, such as cancer, diabetes, Covid-19, hepatitis, human papillomavirus, and other diseases; diagnostic instruments; and digital health solutions. Roche Holding AG was founded in 1896 and is based in Basel, Switzerland.